170 related articles for article (PubMed ID: 7946598)
1. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas.
Manenti G; Pilotti S; Re FC; Della Porta G; Pierotti MA
Eur J Cancer; 1994; 30A(7):987-93. PubMed ID: 7946598
[TBL] [Abstract][Full Text] [Related]
2. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
[TBL] [Abstract][Full Text] [Related]
3. N-ras mutation of thyroid tumor with special reference to the follicular type.
Oyama T; Suzuki T; Hara F; Iino Y; Ishida T; Sakamoto A; Nakajima T
Pathol Int; 1995 Jan; 45(1):45-50. PubMed ID: 7704243
[TBL] [Abstract][Full Text] [Related]
4. Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers.
Bouras M; Bertholon J; Dutrieux-Berger N; Parvaz P; Paulin C; Revol A
Eur J Endocrinol; 1998 Aug; 139(2):209-16. PubMed ID: 9724079
[TBL] [Abstract][Full Text] [Related]
5. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.
Liu RT; Hou CY; You HL; Huang CC; Hock-Liew ; Chou FF; Wang PW; Cheng JT
Thyroid; 2004 Aug; 14(8):616-21. PubMed ID: 15320975
[TBL] [Abstract][Full Text] [Related]
6. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin.
Motoi N; Sakamoto A; Yamochi T; Horiuchi H; Motoi T; Machinami R
Pathol Res Pract; 2000; 196(1):1-7. PubMed ID: 10674266
[TBL] [Abstract][Full Text] [Related]
7. Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma.
Sápi Z; Lukács G; Sztán M; Papp J; Oláh E
Diagn Mol Pathol; 1995 Dec; 4(4):256-60. PubMed ID: 8634781
[TBL] [Abstract][Full Text] [Related]
8. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.
Namba H; Rubin SA; Fagin JA
Mol Endocrinol; 1990 Oct; 4(10):1474-9. PubMed ID: 2283998
[TBL] [Abstract][Full Text] [Related]
9. [Specific amplification by PCR for N-ras mutation in thyroid follicular cartinoma].
Taniyama M; Kaihara M
Nihon Rinsho; 1994 Apr; 52(4):1075-80. PubMed ID: 8196166
[TBL] [Abstract][Full Text] [Related]
10. Specific PCR amplification for N-ras mutations in neoplastic thyroid diseases.
Kaihara M; Taniyama M; Tadatomo J; Tobe T; Tomita M; Ito K; Ban Y; Katagiri T
Endocr J; 1994 Jun; 41(3):301-8. PubMed ID: 7951583
[TBL] [Abstract][Full Text] [Related]
11. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.
Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y
Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231
[TBL] [Abstract][Full Text] [Related]
12. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.
Basolo F; Pisaturo F; Pollina LE; Fontanini G; Elisei R; Molinaro E; Iacconi P; Miccoli P; Pacini F
Thyroid; 2000 Jan; 10(1):19-23. PubMed ID: 10691309
[TBL] [Abstract][Full Text] [Related]
13. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Ras mutations in thyroid neoplasia.
Esapa CT; Johnson SJ; Kendall-Taylor P; Lennard TW; Harris PE
Clin Endocrinol (Oxf); 1999 Apr; 50(4):529-35. PubMed ID: 10468914
[TBL] [Abstract][Full Text] [Related]
15. Clear Cell Change in Thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies.
Cipriani NA; Agarwal S; Dias-Santagata D; Faquin WC; Sadow PM
Thyroid; 2017 Jun; 27(6):819-824. PubMed ID: 28293986
[TBL] [Abstract][Full Text] [Related]
16. Activating mutations of the TSH receptor in differentiated thyroid carcinomas.
Russo D; Arturi F; Schlumberger M; Caillou B; Monier R; Filetti S; Suárez HG
Oncogene; 1995 Nov; 11(9):1907-11. PubMed ID: 7478621
[TBL] [Abstract][Full Text] [Related]
17. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.
Vitagliano D; Portella G; Troncone G; Francione A; Rossi C; Bruno A; Giorgini A; Coluzzi S; Nappi TC; Rothstein JL; Pasquinelli R; Chiappetta G; Terracciano D; Macchia V; Melillo RM; Fusco A; Santoro M
Oncogene; 2006 Aug; 25(39):5467-74. PubMed ID: 16785999
[TBL] [Abstract][Full Text] [Related]
18. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
19. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
20. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours.
Salvatore D; Celetti A; Fabien N; Paulin C; Martelli ML; Battaglia C; Califano D; Monaco C; Viglietto G; Santoro M; Fusco A
Eur J Endocrinol; 1996 Feb; 134(2):177-83. PubMed ID: 8630516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
